Financial Data and Key Metrics Changes - Total revenue in Q4 was $349 million, up 15.6% year-over-year [26] - Full year revenue growth was 15%, with a non-GAAP operating margin of 14%, representing a year-over-year expansion of 400 basis points [7][30] - Q4 non-GAAP operating income was $52 million, with a non-GAAP operating margin of 15% [26] - Free cash flow for Q4 was $90 million, bringing full-year free cash flow to $215 million, representing 69% year-over-year growth [30] Business Line Data and Key Metrics Changes - The U.S. general contractors segment remains a cornerstone of growth, with 3 new ENR 400 logos added in Q4 and over 70 ENR 400 customers expanding their run rate [8][10] - Procore Pay saw strong momentum, ending the year with nearly 450 customers, representing over 70% year-over-year growth [28] - The total number of customers spending over $100K in ARR exceeded 2,700, with 115 customers spending more than $1 million in ARR, reflecting 34% year-over-year growth [27] Market Data and Key Metrics Changes - International revenue grew 14% year-over-year, impacted by currency headwinds, but grew 15% on a constant currency basis [26] - The owners segment continues to scale, with plans to launch specialized products to meet evolving needs [12] Company Strategy and Development Direction - The company aims to lead in the AI era, focusing on driving efficiency gains across the construction lifecycle [6][14] - Procore's strategy includes leveraging its position as a system of record and collaboration to enhance AI capabilities [19][20] - The acquisition of Datagrid is expected to accelerate Procore's AI strategy, enhancing product synergies [16][45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Procore's future, emphasizing the importance of customer relationships and the potential for durable growth and margin expansion [5][25] - The company anticipates continued strength in free cash flow per share and plans to maintain a focus on productivity increases [30][77] - Management acknowledged ongoing headwinds in the construction environment but remains optimistic about the company's ability to navigate these challenges [7][32] Other Important Information - Procore for Government achieved FedRAMP Moderate authorization, expanding opportunities with U.S. federal and state government customers [12] - The company is focused on limiting share count dilution, with a weighted average diluted share count growing less than 1% in Q4 [30] Q&A Session Summary Question: Customer conversations regarding AI - Management noted that customers are not inclined to become AI experts and prefer their tech vendor to leverage the latest technologies, including AI [39][40] Question: Glide path for CRPO growth - Management indicated that CRPO growth will normalize with revenue growth as contract duration stabilizes, expected towards the latter part of fiscal 2026 [46][47] Question: Competitive landscape and Procore's position - Management highlighted strong competitive win rates and positive customer relationships, reflecting confidence in Procore's technology and platform [50][57] Question: International growth opportunities - Management acknowledged macroeconomic challenges but remains optimistic about the long-term potential for international growth [60][61] Question: Monetization strategy for AI - Management discussed establishing a compelling ROI for AI and indicated plans to include AI offerings in upcoming bundles and explore consumption-based models [75][76]

Financial Data and Key Metrics Changes - For 2025, the company reported total revenue of $673 million, representing a 20% growth over 2024, exceeding the upper end of guidance [10] - The net loss for the year was $575 million, or $5.83 per share, with cash, cash equivalents, and marketable securities totaling $738 million as of December 31 [11] Business Line Data and Key Metrics Changes - Crysvita contributed $481 million, with a 17% growth over 2024, exceeding guidance [10] - Dojolvi generated $96 million, reflecting a 9% growth over 2024 [10] - Evkeeza saw significant growth, contributing $59 million, representing an 84% increase over 2024 [10] - Mepsevii contributed $37 million, continuing to treat patients in an ultra-rare indication [10] Market Data and Key Metrics Changes - The commercial business delivered a significant 20% year-over-year growth in 2025, with treatments reaching over 35 countries [6] - The company anticipates total revenue in 2026 to be between $730 million and $760 million, representing an 8%-13% growth over 2025 [11][12] Company Strategy and Development Direction - The company is focused on achieving profitability by 2027 through a strategic restructuring plan that includes a 10% workforce reduction and realignment of resources towards high-impact opportunities [7][9] - The company aims to launch three additional treatments over the next two years while continuing to grow its existing commercial products [9][22] Management's Comments on Operating Environment and Future Outlook - Management highlighted 2026 as a significant year with potential approvals in key programs and pivotal data readouts [3] - The company is addressing the FDA's incomplete response letter regarding UX111 and is working to provide additional documentation for resubmission [5][20] - Management expressed confidence in the ability to deliver the next phase of growth required to reach profitability [19] Other Important Information - The company is implementing a strategic restructuring plan to reduce operating expenses while advancing its product pipeline [7][9] - The company expects combined R&D and SG&A expenses to be flat to down low single digits in 2026 compared to 2025 [12] Q&A Session Summary Question: Regarding the primary endpoint for the phase 3 Angelman study - The decision to use cognition over expressive communication was based on its fundamental importance and the complexities of communication development [24][25] Question: Can you provide insights on the patient baseline profile for the phase 3 study? - The baseline data from the phase 3 program is comparable to the expansion trial, providing confidence in the study's design [29][30] Question: How does the company plan to achieve profitability in 2027? - The pathway to profitability includes continued growth from current products and cost reductions, with expectations for combined R&D and SG&A expenses to decrease significantly by 2027 [35][36] Question: Can you clarify the timeline for the IRL resubmission? - The resubmission timeline is similar to the original submission, with a PDUFA date expected approximately six months after resubmission [68][69] Question: What is the expected launch trajectory for DTX-401? - The launch is expected to develop steadily, with strong demand anticipated, but not an immediate steep uptake [72]

Federal Realty Investment Trust (NYSE:FRT) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Speaker13Good day, and welcome to the Federal Realty Investment Trust fourth quarter 2025 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypa ...

Summary of Amgen Conference Call - February 12, 2026 Company Overview - **Company**: Amgen (NasdaqGS:AMGN) - **Focus**: Development of innovative therapies for autoimmune diseases and other conditions Key Products and Developments UPLIZNA - **Indications**: Plans to initiate Phase III studies for autoimmune hepatitis (AIH) and chronic inflammatory demyelinating polyneuropathy (CIDP) later in 2026 - **Mechanism**: B-cell depleter targeting CD19, effective in conditions driven by pathogenic B-cells - **Market Potential**: - CIDP prevalent pool in the U.S. estimated at 35,000 patients, with 7,000-10,000 new cases annually - AIH likely has a larger patient population, though exact numbers are difficult to ascertain - **Rationale**: Proven effectiveness in similar conditions like IgG4-related disease and generalized myasthenia gravis supports the potential for UPLIZNA in AIH and CIDP [1][2][3][4][6] Daxdilimab - **Indications**: Positive Phase II results in discoid lupus; previously failed in systemic lupus erythematosus (SLE) - **Mechanism**: Targets immunoglobulin-like transcript seven protein (ILT-7), depleting plasmacytoid dendritic cells involved in interferon production - **Clinical Results**: - Discoid lupus study met primary endpoint of reduced disease severity at week 24 - Secondary endpoint also showed clinical benefit - **Future Plans**: Considering Phase III study for discoid lupus, with potential for broader indications in autoimmune diseases driven by plasmacytoid dendritic cells [9][10][11][13][16] Dazodalibep - **Indications**: Targeting Sjögren's syndrome with two ongoing Phase III studies - **Mechanism**: Inhibits CD40 ligand, disrupting B-cell activation and downstream inflammatory cascades - **Clinical Management**: Current management is symptomatic; no definitive treatments exist - **Phase II Results**: Showed improvement in disease activity index and patient-reported outcomes, providing confidence for Phase III studies [18][26][29][32] TEZSPIRE - **Indications**: Recently expanded label for chronic rhinosinusitis with nasal polyps - **Mechanism**: Targets TSLP, addressing upstream drivers of inflammation, differentiating it from therapies targeting downstream cytokines (IL-4, IL-5, IL-13) - **Clinical Results**: Phase 3 Waypoint study showed significant reduction in nasal polyp severity and decreased need for surgery - **Market Potential**: High overlap between chronic rhinosinusitis and asthma (approximately 20% of asthma patients also have nasal polyps), enhancing TEZSPIRE's market reach [35][36][37][42][45] Eosinophilic Esophagitis (EoE) - **Unmet Need**: Current treatments are limited, primarily involving proton pump inhibitors and corticosteroids - **Prevalence**: Estimated at 1 in 700 people in the U.S. - **Phase III Study**: Expected data in the second half of 2026, with potential for TEZSPIRE to address this unmet need [47][49][51] Competitive Landscape - **Dazodalibep vs. Nipocalimab**: Dazodalibep is the first therapy to demonstrate efficacy in both subgroups of Sjögren's syndrome in Phase II, with ongoing Phase III studies to confirm its effectiveness [32][34] Future Outlook - **Execution Focus**: Amgen aims to build penetration in existing indications before exploring new ones for TSLP-targeted therapies - **Inhaled TSLP Therapy**: AMG 104, an inhaled TSLP antibody fragment, is in Phase II trials, with potential to provide an alternative to injected biologics for asthma management [65][66][70][74] Conclusion - Amgen is positioned to leverage its innovative therapies across multiple autoimmune conditions, with significant clinical data supporting the efficacy of its products. The company is focused on executing its current strategies while preparing for future opportunities in the evolving therapeutic landscape.

Toast (NYSE:TOST) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Speaker8Good afternoon. My name is Tiffany, and I will be your conference operator today. At this time, I would like to welcome everyone to Toast's fourth quarter and full year 2025 earnings conference call. Today's call will be 45 minutes. I'll now turn the call over to Michael Senno, Senior Vice President of Finance. You may begin your conference.Speaker7Thank you, operator. Welcome to Toast's earnings conference call for the fourth qua ...

Yelp (NYSE:YELP) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Speaker7Thank you for standing by. At this time, I would like to welcome everyone to today's Q4 2025 Yelp Incorporated Earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, simply press star, followed by the number one on your telephone keypad. Once again, star one. If you'd lik ...

Bannerman Energy (OTCPK:BNNL.F) Update / briefing February 12, 2026 04:45 PM ET Company ParticipantsAndrew Hines - Head of ResearchBrandon Munro - Executive ChairmanGlyn Lawcock - Founding Partner and Head of Resources ResearchMilan Tomic - Metals and Mining AssociateOperatorThank you. I'd now like to welcome Brandon Munro, Executive Chairman, to begin the conference. Brandon, over to you.Brandon MunroThanks very much everyone for joining us. It's really a transformational and very exciting moment in the co ...

Financial Data and Key Metrics Changes - Revenue for Q2 2026 was $14.1 million, an increase from $13.2 million in the prior quarter but a decrease from $16.8 million in the same quarter last year [16] - Gross margin improved to 34.7% from 28.6% in the prior quarter and 32.5% in the prior year, reflecting a 610 basis point sequential increase due to improved product mix and cost-saving initiatives [16] - Operating expenses decreased to $4.1 million from $5.9 million in the prior quarter and $6.9 million in Q2 2025, marking a 31% sequential decrease [17] - Net income for Q2 was $0.6 million, or $0.03 per share, compared to a net loss of $2.6 million in the prior quarter and a net loss of $1.9 million in Q2 2025 [17] - Non-GAAP net income was $1 million, or $0.04 per share, compared to a net loss of $2 million in the prior quarter [18] Business Line Data and Key Metrics Changes - The company achieved net profitability for the first time in its history, attributed to expense optimization and revenue growth [4][5] - The introduction of the SkyLink telematics device is expected to enhance product offerings and customer engagement [9][10] Market Data and Key Metrics Changes - The lithium-ion forklift battery segment is projected to grow at an 8.8% CAGR through 2035, indicating strong long-term market opportunities [15] - The company is experiencing a capital freeze from its most significant customer, which may impact revenue for a significant portion of calendar year 2026 [14] Company Strategy and Development Direction - The company is focused on five strategic initiatives: profitable growth, operational efficiencies, solution selling, building the right products, and integrating value-added software [5] - The company is enhancing its product line and energy system software using AI to improve operational efficiencies [20] - There is a strong emphasis on solution-based selling, moving beyond just battery sales to energy management solutions [7][10] Management's Comments on Operating Environment and Future Outlook - Management noted that while there are challenges due to tariffs and a capital freeze from a key customer, they remain optimistic about the long-term market potential [14][15] - The company is taking proactive measures to reduce expenses and is well-positioned to respond to customer needs despite short-term pressures [15][20] Other Important Information - The company has made significant progress in product development, including the release of the next-generation SkyLink telematics device and the GAT 315 battery [10][11] - The SkyEMS software has been upgraded to include new features that enhance fleet management and productivity [11] Q&A Session Summary Question: Is the capital freeze unique to one customer or widespread in the industry? - Management confirmed that the capital freeze is specific to one customer [23] Question: How is the overall demand environment looking? - Management indicated that demand is stable but affected by lingering tariff effects [24] Question: What is the rollout strategy for the SkyLink product? - The SkyLink telematics will be offered across the product line, with positive initial feedback from beta tests [25][26] Question: Will cost savings and warranty costs remain low? - Management expects continued positive trends in warranty and repair costs, contributing to improved gross margins [30][31] Question: How does the company plan to fill the revenue gap from the capital freeze? - The company is actively hiring new sales personnel and focusing on increasing adoption of lithium batteries [36][37] Question: Will new SkyLink features be sold at a premium? - Management plans to offer a tiered software package, with premium features expected to have significantly higher gross margins [38][39] Question: Can you elaborate on the State of Health patent and its revenue potential? - The patent includes algorithms for battery health insights, which will be part of a premium software package, generating potential revenue [41][42]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $20.1 million, up 16% sequentially and 30% year-over-year, exceeding guidance [20] - Full year 2025 total revenue reached $70.6 million, a 22% increase year-over-year [20] - Annual contract value plus royalties was $83.6 million, a 28% year-over-year increase, marking a new record [21] - Remaining performance obligations (RPO) totaled $117 million, representing a 32% year-over-year increase, another record high [21] - Non-GAAP gross profit for Q4 was $18.5 million, with a gross margin of 92% [22] - GAAP operating loss for Q4 was $8.5 million, compared to a loss of $7.1 million in the prior year [25] Business Line Data and Key Metrics Changes - Variable royalties increased by 50% year-over-year, with Q4 setting a new record [20] - FlexGen, an AI-driven smart NoC IP product, saw strong customer adoption, licensed for over 30 production device deployments [11] - Ncore, a cache coherent interconnect IP product, also experienced strength in licensing across various edge and server applications [12] Market Data and Key Metrics Changes - The largest impacts on revenue were seen in enterprise computing, automotive, and consumer electronics markets [7] - The number of large royalty reporters tripled in the last two years, indicating a diversified customer base [20] Company Strategy and Development Direction - The acquisition of Cycuity enhances Arteris' product portfolio, focusing on semiconductor cybersecurity assurance [8] - The company aims to address the growing need for cybersecurity in semiconductor designs, which is becoming a major issue [10] - Arteris is positioned to support semiconductor applications in the AI era across various sectors, including automotive and aerospace [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, expecting to report a non-GAAP operating profit as early as Q4 2026 [28] - The company anticipates continued strong demand for its products driven by the proliferation of AI-driven semiconductor designs [7] Other Important Information - Free cash flow was positive $3 million for Q4 and positive $5.3 million for the full year [26] - The company ended the year with $59.5 million in cash and no financial debt [26] Q&A Session Summary Question: Cross-sell opportunities and customer segments - Management highlighted that hardware security assurance is a major issue, opening significant cross-sell opportunities across the semiconductor industry [30][31] Question: NXP's increased use of Arteris solutions - Management confirmed that deploying multiple solutions increases average selling prices significantly, especially with the addition of Cycuity [35][36] Question: Strength in royalties and market segments - Management noted that the growth in royalties was due to both customer diversification and strength in various market segments, particularly automotive [37][38] Question: Impact of security acquisition on P&L - Management indicated that approximately $7 million of the projected revenue for 2026 would come from Cycuity, with expectations of breakeven by Q4 2026 [45][46]

Artivion (NYSE:AORT) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsBill Plovanic - Managing Director and Healthcare Equity ResearchDaniel Stoter - VP of Equity ResearchLance Berry - COO and CFOLane Morgan - Associate Vice PresidentPat Mackin - CEOConference Call ParticipantsJohn McCalley - Equity Research AnalystMike Matson - Managing Director and Senior Equity Research AnalystNone - AnalystNone - AnalystOperatorGood afternoon, and welcome to the Artivion fourth quarter and year-en ...